Showing results (51-60 of 120) with videos related to

Sort By:
Pageof 12
Biorxiv : the Preprint Server for Biology|June 19, 2023
Alteration of DNMT1/DNMT3A by eribulin elicits global DNA methylation changes with potential therapeutic implications for triple-negative breast cancerMeisam Bagheri, Min Kyung Lee, Kristen E Muller, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 12, 2017
Autophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor-positive breast cancerWei Yang, Sarah R Hosford, Nicole A Traphagen, et al.
Epigenomics|February 15, 2024
Alteration of DNA methyltransferases by eribulin elicits broad DNA methylation changes with potential therapeutic implications for triple-negative breast cancerMeisam Bagheri, Min Kyung Lee, Kristen E Muller, et al.
Plos One|November 9, 2016
Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In SituDavid C Butler, Shubhada N Joshi, Erwin De Genst, et al.
NPJ Parkinson'S Disease|August 30, 2018
Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson's disease modelDiptaman Chatterjee, Mansi Bhatt, David Butler, et al.
Biochemistry|March 10, 2004
Inhibiting aggregation of alpha-synuclein with human single chain antibody fragmentsSharareh Emadi, Ruitian Liu, Bin Yuan, et al.
Oncotarget|March 7, 2018
Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancerWei Yang, Gary N Schwartz, Jonathan D Marotti, et al.
Gene Therapy|March 23, 2021
Enhanced CNS transduction from AAV.PHP.eB infusion into the cisterna magna of older adult rats compared to AAV9Diptaman Chatterjee, David J Marmion, Jodi L McBride, et al.
Oncogene|April 20, 2021
High estrogen receptor alpha activation confers resistance to estrogen deprivation and is required for therapeutic response to estrogen in breast cancerNicole A Traphagen, Sarah R Hosford, Amanda Jiang, et al.
Case Reports in Oncology|January 20, 2017
Maximizing the Benefit-Cost Ratio of Anthracyclines in Metastatic Breast Cancer: Case Report of a Patient with a Complete Response to High-Dose DoxorubicinKevin Shee, Alan T Kono, Susan P D'Anna, et al.
Pageof 12